BioLife Solutions (NASDAQ:BLFS) Cut to "Sell" at StockNews.com

BioLife Solutions (NASDAQ:BLFS - Get Free Report) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.17.

BioLife Solutions Stock Down 0.6%

Shares of BLFS stock opened at $22.81 on Wednesday. BioLife Solutions has a 12-month low of $18.70 and a 12-month high of $29.55. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average of $23.41 and a 200-day moving average of $25.28. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -21.52 and a beta of 2.01.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $23.94 million during the quarter, compared to analysts' expectations of $22.22 million. As a group, equities research analysts predict that BioLife Solutions will post -0.3 earnings per share for the current fiscal year.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,589 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $239,946.74. Following the completion of the transaction, the executive vice president now directly owns 309,576 shares in the company, valued at $7,014,992.16. This trade represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Troy Wichterman sold 4,151 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $103,775.00. Following the sale, the chief financial officer now owns 116,809 shares in the company, valued at approximately $2,920,225. This represents a 3.43% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,696 shares of company stock valued at $1,665,094. 2.20% of the stock is owned by insiders.

Institutional Trading of BioLife Solutions

A number of large investors have recently added to or reduced their stakes in BLFS. Steward Partners Investment Advisory LLC acquired a new position in shares of BioLife Solutions during the 4th quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions during the fourth quarter worth about $31,000. State of Wyoming increased its position in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock worth $44,000 after buying an additional 1,490 shares during the last quarter. US Bancorp DE raised its stake in BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after buying an additional 1,528 shares during the period. Finally, 1620 Investment Advisors Inc. raised its stake in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares during the period. Institutional investors and hedge funds own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.